Children with liver disease present complex and varied acquired coagulation abnormalities Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components Although 75 85 of patients with liver disease show abnormal laboratory values only 10 15 will have clinical bleeding symptoms as liver has a large factor reserve capacity This paper will review acute and chronic liver disease and the hemostatic alterations Treatment of the coagulopaty of liver disease is usually replacement of lacking factor and supportive care Liver transplantation which is very common recently and its affects on hematological balance will also summarized Turk Arch Ped 2013; 48: 94 101
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Children with liver disease present complex and varied acquired coagulation abnormalities Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components Although 75 85 of patients with liver disease show abnormal laboratory values only 10 15 will have clinical bleeding symptoms as liver has a large factor reserve capacity This paper will review acute and chronic liver disease and the hemostatic alterations Treatment of the coagulopaty of liver disease is usually replacement of lacking factor and supportive care Liver transplantation which is very common recently and its affects on hematological balance will also summarized Turk Arch Ped 2013; 48: 94 101
📊
Key Findings & Data:Children with liver disease present complex and varied acquired coagulation abnormalities Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components Although 75 85 of patients with liver disease show abnormal laboratory values only 10 15 will have clinical bleeding symptoms as liver has a large factor reserve capacity This paper will review acute and chronic liver disease and the hemostatic alterations Treatment of the coagulopaty of liver disease is usually replacement of lacking factor and supportive care Liver transplantation which is very common recently and its affects on hematological balance will also summarized Turk Arch Ped 2013; 48: 94 101
💡
Conclusion & Impact:Children with liver disease present complex and varied acquired coagulation abnormalities Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components Although 75 85 of patients with liver disease show abnormal laboratory values only 10 15 will have clinical bleeding symptoms as liver has a large factor reserve capacity This paper will review acute and chronic liver disease and the hemostatic alterations Treatment of the coagulopaty of liver disease is usually replacement of lacking factor and supportive care Liver transplantation which is very common recently and its affects on hematological balance will also summarized Turk Arch Ped 2013; 48: 94 101
Children with liver disease present complex and varied acquired coagulation abnormalities Liver is the place where clotting factors are produced as well as inhibitors of coagulation and fibrinolytic system components Although 75 85 of patients with liver disease show abnormal laboratory values only 10 15 will have clinical bleeding symptoms as liver has a large factor reserve capacity This paper will review acute and chronic liver disease and the hemostatic alterations Treatment of the coagulopaty of liver disease is usually replacement of lacking factor and supportive care Liver transplantation which is very common recently and its affects on hematological balance will also summarized Turk Arch Ped 2013; 48: 94 101
Özet
Karaciğer hastalığı olan çocuklar karışık ve değişken pıhtılaşma bozuklukları gösterirler Pıhtılaşma faktörleri gibi pıhtılaşmayı engelleyen faktörler ve fibrinoliz karaciğerde yapılır Karaciğer hastalarının 75 85 rsquo;inde laboratuvarda bozukluk olsa da bu hastaların 10 15 rsquo;inde klinik kanama bulgusu vardır çünkü bu faktörler için karaciğerin geniş bir birikimi söz konusudur Bu yazıda akut ve kronik karaciğer hastalıklarında karaciğerin hemostatik özelliklerinden bahsedilecektir Karaciğer hastasının kanamasında genellikle eksik olan faktörün yerine konulması ve destek tedavisi önem kazanır Son yıllarda artan sayıda yapılan karaciğer nakli ve hematolojik sonuçlarından da bahsedilecektir.
Celkan, T. T. (2013). What happens to coagulation thrombosis mechanism in liver diseases?. Türk Pediatri Arşivi, Cilt: 48 Sayı: 2, 94–101. https://ajindex.com/articles/1011683
Joist JH, George JN. Hemostatic abnormalities in liver and renal disease. In: Colman RW, Hirsh J, Marder VJ, Clowes AE, George JN, (eds). Hemostasis and thrombosis. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001: 955-73.
Monroe DM, Hoffman M. The coagulation cascade in cirrhosis. Clin Liver Dis 2009; 13(1): 1-9.
Lisman T, Caldwell SH, Burroughs AK, et al. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53(2): 362-71.
Gugig R, Rosenthal P. Current options for treatment of end-stage liver disease in children. Curr Pediatr Rev 2005; 1: 261-4.
Leebeek FW, Kluft C, Knot EA, de Maat MP, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101: 1382Ferro D, Quintarelli C, Saliola M, et al. Prevalence of hyperfibrinolysis in patients with liver cirrhosis. Fibrinolysis 1993; 7(1): 59-62.
Francis RB Jr, Feinstein DI. Clinical significance of accelerated fibrinolysis in liver disease. Haemostasis 1984; 14(6): 460-5.
Ben-Ari Z, Osman E, Hutton RA, Burroughs AK. Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol 1999; 94(10): 2977-82.
Ryan BM, Stockbrugger RW, Ryan JM. A pathophysiologic, gastroenterologic, and radiologic approach to the management of gastric varices. Gastroenterology 2004; 126(4): 1175-89.
Smalberg JH, Leebeek FW. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis 2009; 13(1): 33-42.
Lisman T, Porte RJ, Leebeek FW, Caldwell SH. Methodological issues with coagulation testing in patients with liver disease. 2006; 4(9): 2061-2. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4(4): 721-3. Reverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb Haemost 2006; 4(4): 717-20.
Lisman T, Caldwell SH, Porte RJ, Leebeek FW. Consequences of abnormal hemostasis tests for clinical practice. J Thromb Haemost 2006; 4(9): 2062-3.
Cattaneo M, Tenconi PM, Alberca I, Garcia VV, Mannucci PM. Subcutaneous desmopressin (DDAVP) shortens the prolonged bleeding time in patients with liver cirrhosis. Thromb Haemost 1990; 64(3): 358-60.
Friedman EW, Sussman II. Safety of invasive procedures in patients with the coagulopathy of liver disease. Clin Lab Haematol 1989; 1